Loading...
Header Logo
Keywords
Last Name
Institution

NATHAN FOWLER

TitleAssociate Professor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma. 2020 Jul 06; 1-5. PMID: 32628087.
      View in: PubMed
    2. Flowers CR, Leonard JP, Fowler NH. Lenalidomide in follicular lymphoma. Blood. 2020 Jun 11; 135(24):2133-2136. PMID: 32236519.
      View in: PubMed
    3. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020 06; 95(6):623-629. PMID: 32239765.
      View in: PubMed
    4. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 Mar 24; 4(6):1038-1050. PMID: 32191807.
      View in: PubMed
    5. Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK, Palomba ML. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Br J Haematol. 2020 May; 189(4):650-660. PMID: 32180219.
      View in: PubMed
    6. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma. 2020 Jun; 61(6):1380-1387. PMID: 31971032.
      View in: PubMed
    7. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 11 21; 134(21):1811-1820. PMID: 31558467.
      View in: PubMed
    8. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. 2020 Jul; 105(7):1907-1913. PMID: 31601688.
      View in: PubMed
    9. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 Feb; 61(2):328-336. PMID: 31533521.
      View in: PubMed
    10. Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Lee HJ, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma. 2020 01; 61(1):171-175. PMID: 31373240.
      View in: PubMed
    11. Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS. Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Leuk Lymphoma. 2019 12; 60(13):3258-3265. PMID: 31234671.
      View in: PubMed
    12. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103. PMID: 31141631.
      View in: PubMed
    13. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv. 2019 05 14; 3(9):1356-1367. PMID: 31036721.
      View in: PubMed
    14. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020 Jan; 105(1):e26-e28. PMID: 31073068.
      View in: PubMed
    15. Sagiv O, Thakar SD, Manning JT, Kandl TJ, Fayad LE, Fowler N, Hagemeister FB, Fanale MA, Pinnix CC, Samaniego F, Esmaeli B. Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. Ophthalmic Plast Reconstr Surg. 2019 May/Jun; 35(3):243-246. PMID: 30124609.
      View in: PubMed
    16. Barta SK, Zain J, MacFarlane AW, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):356-364.e3. PMID: 31029646.
      View in: PubMed
    17. Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leuk Lymphoma. 2019 10; 60(10):2432-2440. PMID: 30942648.
      View in: PubMed
    18. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882. PMID: 30919940.
      View in: PubMed
    19. Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019 05 10; 37(14):1188-1199. PMID: 30897038.
      View in: PubMed
    20. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2019 May; 41(5):1546. PMID: 30990235.
      View in: PubMed
    21. Dandachi D, Ostrom QT, Chong I, Serpa JA, Giordano TP, Kruchko C, Barnholtz-Sloan JS, Fowler N, Colen RR, Morón FE. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. Cancer Causes Control. 2019 May; 30(5):477-488. PMID: 30888569.
      View in: PubMed
    22. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol. 2019 06; 94(6):E150-E153. PMID: 30785215.
      View in: PubMed
    23. Andraos T, Ayoub Z, Nastoupil L, Pinnix C, Milgrom S, Gunther J, Ng SP, Fowler N, Neelapu S, Samaniego F, Dabaja B. Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):381-389. PMID: 30935940.
      View in: PubMed
    24. Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Amini B, Neelapu S, Lee HJ, Westin J, Fowler N, Nastoupil L, Dabaja B. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2019 06 01; 104(2):447-455. PMID: 30769175.
      View in: PubMed
    25. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346. PMID: 30763728.
      View in: PubMed
    26. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb; 6(2):e100-e109. PMID: 30709431.
      View in: PubMed
    27. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Ann Hematol. 2019 May; 98(5):1169-1176. PMID: 30617643.
      View in: PubMed
    28. Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018 11 16; 6(1):119. PMID: 30446007.
      View in: PubMed
    29. Fountain E, Mistry H, Jain P, Duvic M, Fowler N. Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides. Leuk Lymphoma. 2019 04; 60(4):1079-1082. PMID: 30301395.
      View in: PubMed
    30. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61. PMID: 30360985.
      View in: PubMed
    31. Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med. 2018 09 06; 379(10):934-947. PMID: 30184451.
      View in: PubMed
    32. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018 11; 183(4):578-587. PMID: 30175400.
      View in: PubMed
    33. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646. PMID: 30370365.
      View in: PubMed
    34. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019 04; 185(2):334-338. PMID: 29978452.
      View in: PubMed
    35. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018 Jun 22; 9(48):28897-28902. PMID: 29988979.
      View in: PubMed
    36. Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol. 2018 08 10; 36(23):2405-2412. PMID: 29851546.
      View in: PubMed
    37. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018 08; 182(3):404-411. PMID: 29785709.
      View in: PubMed
    38. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569. PMID: 29723393.
      View in: PubMed
    39. Coutre SE, Flinn IW, de Vos S, Barrientos JC, Schreeder MT, Wagner-Johnson ND, Sharman JP, Boyd TE, Fowler N, Dreiling L, Kim Y, Mitra S, Rai K, Leonard JP, Furman RR. Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. Hemasphere. 2018 Jun; 2(3):e39. PMID: 31723767.
      View in: PubMed
    40. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica. 2018 09; 103(9):e416-e418. PMID: 29622656.
      View in: PubMed
    41. Cheson BD, Chua N, Mayer J, Dueck G, Trnený M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol. 2018 08 01; 36(22):2259-2266. PMID: 29584548.
      View in: PubMed
    42. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461. PMID: 29538376.
      View in: PubMed
    43. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2018 06; 40(6):1335. PMID: 29851218.
      View in: PubMed
    44. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154. PMID: 29452771.
      View in: PubMed
    45. Cheah CY, Fowler NH. Novel agents for relapsed and refractory follicular lymphoma. Best Pract Res Clin Haematol. 2018 03; 31(1):41-48. PMID: 29452665.
      View in: PubMed
    46. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108. PMID: 29196178.
      View in: PubMed
    47. Li X, Xu-Monette ZY, Yi S, Dabaja BS, Manyam GC, Westin J, Fowler N, Miranda RN, Zhang M, Ferry JA, Medeiros LJ, Harris NL, Young KH. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol. 2017 Oct; 41(10):1309-1321. PMID: 28817403.
      View in: PubMed
    48. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthalmic Plast Reconstr Surg. 2017 Sep/Oct; 33(5):355-360. PMID: 27636243.
      View in: PubMed
    49. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870. PMID: 28792260.
      View in: PubMed
    50. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol. 2018 09; 182(5):718-723. PMID: 28771675.
      View in: PubMed
    51. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477. PMID: 28522441.
      View in: PubMed
    52. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844. PMID: 28482717.
      View in: PubMed
    53. Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler N. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. 2017 08; 178(3):403-412. PMID: 28382648.
      View in: PubMed
    54. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017 06; 39(6):1095-1100. PMID: 28370694.
      View in: PubMed
    55. Mistry H, Forbes SG, Fowler N. Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm?. Clin J Oncol Nurs. 2017 04 01; 21(2 Suppl):53-59. PMID: 28315558.
      View in: PubMed
    56. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017 04; 177(2):263-270. PMID: 28340281.
      View in: PubMed
    57. Fowler NH. Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary. Clin Adv Hematol Oncol. 2017 Mar; 15 Suppl 3(3):21-23. PMID: 28590462.
      View in: PubMed
    58. Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. Recommendations for Clinical Trial Development in Follicular Lymphoma. J Natl Cancer Inst. 2017 03; 109(3). PMID: 28040699.
      View in: PubMed
    59. Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017 Jun; 14(6):335-346. PMID: 28031560.
      View in: PubMed
    60. Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. J Clin Oncol. 2017 Feb 10; 35(5):552-560. PMID: 28029309.
      View in: PubMed
    61. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758. PMID: 27983760.
      View in: PubMed
    62. Jain P, Prieto VG, Manning JT, Fowler N, Medeiros LJ, Kanagal-Shamanna R. Synchronous presentation of intra-nodal follicular dendritic cell sarcoma and Castleman disease. Am J Hematol. 2017 May; 92(5):478-479. PMID: 27862216.
      View in: PubMed
    63. Fowler N. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy? Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):277-283. PMID: 27913492.
      View in: PubMed
    64. de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP. Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. Blood Adv. 2016 Dec 13; 1(2):122-131. PMID: 29296805.
      View in: PubMed
    65. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol. 2017 12; 179(5):851-854. PMID: 27502933.
      View in: PubMed
    66. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9. PMID: 27227654.
      View in: PubMed
    67. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ß2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299. PMID: 27448187.
      View in: PubMed
    68. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506. PMID: 27378601.
      View in: PubMed
    69. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151. PMID: 27351173.
      View in: PubMed
    70. Sehn LH, Chua N, Mayer J, Dueck G, Trnený M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug; 17(8):1081-1093. PMID: 27345636.
      View in: PubMed
    71. Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016 07 21; 128(3):331-6. PMID: 27252232.
      View in: PubMed
    72. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016 05; 101(5):531-40. PMID: 27132279.
      View in: PubMed
    73. Milgrom SA, Cheah CY, Pinnix CC, Smith GL, Dabaja BS, Horace P, Chevez-Barrios P, Fowler NH, Gombos DS. Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. Leuk Lymphoma. 2016 11; 57(11):2612-8. PMID: 27075636.
      View in: PubMed
    74. Kim MM, Dabaja BS, Medeiros J, Kim S, Allen P, Chevez-Barrios P, Gombos DS, Fowler N. Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience. Am J Clin Oncol. 2016 Apr; 39(2):109-13. PMID: 24390272.
      View in: PubMed
    75. Cheah CY, Mistry HE, Konoplev S, Fowler NH. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma. 2016 08; 57(8):1974-6. PMID: 26762971.
      View in: PubMed
    76. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. 2016 11; 175(3):531-533. PMID: 26683805.
      View in: PubMed
    77. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18; 7(314):314ra185. PMID: 26582900.
      View in: PubMed
    78. Mahale P, Turturro F, Romaguera JE, Fowler N, Torres HA. The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia. Leuk Lymphoma. 2016; 57(6):1487-90. PMID: 26402559.
      View in: PubMed
    79. Cheah CY, Milgrom S, Chihara D, Gombos DS, Pinnix CC, Dabaja BS, Fowler NH. Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro Oncol. 2016 Apr; 18(4):575-81. PMID: 26487691.
      View in: PubMed
    80. Cheah CY, Fowler NH. Chemotherapy-Free Treatment of Follicular Lymphoma: We Have the Ingredients, Now for Some Recipes. Oncology (Williston Park). 2015 Oct; 29(10):769, 772. PMID: 26470902.
      View in: PubMed
    81. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol. 2015 Sep 25; 10:206. PMID: 26407853.
      View in: PubMed
    82. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140.
      View in: PubMed
    83. Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol. 2015 Sep; 27(5):384-91. PMID: 26248256.
      View in: PubMed
    84. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16. PMID: 26260306.
      View in: PubMed
    85. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. 2015 Nov; 100(11):e454-7. PMID: 26250576.
      View in: PubMed
    86. Reddy JP, Akhtari M, Smith GL, Pinnix C, Osborne EM, Gunther JR, Allen PK, Yehia ZA, Fanale M, Rodriguez MA, Fowler N, Milgrom SA, Wogan CF, Dabaja BS. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):664-670.e2. PMID: 26321471.
      View in: PubMed
    87. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015 Nov; 171(4):463-70. PMID: 26213141.
      View in: PubMed
    88. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug; 21(8):922-6. PMID: 26193343.
      View in: PubMed
    89. Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2015 Sep 01; 33(25):2803-11. PMID: 26195701.
      View in: PubMed
    90. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015 May 21; 125(21):3357-9. PMID: 25999447.
      View in: PubMed
    91. Akhtari M, Reddy JP, Pinnix CC, Allen PK, Osborne EM, Gunther JR, Milgrom SA, Smith GL, Wogan CF, Fowler N, Rodriguez MA, Dabaja B. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leuk Lymphoma. 2016; 57(1):34-8. PMID: 25860237.
      View in: PubMed
    92. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82. PMID: 25863764.
      View in: PubMed
    93. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21. PMID: 25863759.
      View in: PubMed
    94. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2015 Jul; 100(7):e272-4. PMID: 25820332.
      View in: PubMed
    95. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179. PMID: 25712454.
      View in: PubMed
    96. Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, Offner F, Bron D, Quick D, Fowler N. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Ann Hematol. 2015 Apr; 94(4):633-41. PMID: 25630297.
      View in: PubMed
    97. Torres HA, Mahale P, Blechacz B, Miller E, Kaseb A, Herlong HF, Fowler N, Jiang Y, Raad II, Kontoyiannis DP. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw. 2015 Jan; 13(1):41-50. PMID: 25583768.
      View in: PubMed
    98. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8. PMID: 25439689.
      View in: PubMed
    99. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8. PMID: 25445468.
      View in: PubMed
    100. Fowler NH. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma. Clin Adv Hematol Oncol. 2014 Sep; 12(9):608-10. PMID: 25654483.
      View in: PubMed
    101. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84. PMID: 25039868.
      View in: PubMed
    102. Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol. 2014 Oct; 167(2):207-13. PMID: 25040450.
      View in: PubMed
    103. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901. PMID: 24943107.
      View in: PubMed
    104. Liao B, Kamiya-Matsuoka C, Gong Y, Chen M, Wolf BA, Fowler NH. Primary natural killer/T-cell lymphoma presenting as leptomeningeal disease. J Neurol Sci. 2014 Aug 15; 343(1-2):46-50. PMID: 24880537.
      View in: PubMed
    105. Fowler N. Indolent and mantle cell NHL: the future is BRIGHT. Blood. 2014 May 08; 123(19):2905-6. PMID: 24810622.
      View in: PubMed
    106. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6. PMID: 24386943.
      View in: PubMed
    107. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77. PMID: 24332512.
      View in: PubMed
    108. Kahl BS, Fowler NH, Czuczman MS. Integrating emerging treatment options in mantle cell lymphoma. Clin Adv Hematol Oncol. 2013 Dec; 11(12 Suppl 19):1-15. PMID: 24893155.
      View in: PubMed
    109. Fowler NH. Frontline management strategies for younger, fit patients with mantle cell lymphoma. Clin Adv Hematol Oncol. 2013 Dec; 11 Suppl 19(12):4-6. PMID: 25856246.
      View in: PubMed
    110. Rosen ST, Link BK, Fowler NH. Unmet needs in the treatment of mantle cell lymphoma. Clin Adv Hematol Oncol. 2013 Nov; 11(11 Suppl 18):1-19. PMID: 24893041.
      View in: PubMed
    111. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013 Dec 15; 19(24):6882-90. PMID: 24097867.
      View in: PubMed
    112. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20. PMID: 24117234.
      View in: PubMed
    113. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2014 May; 55(5):1013-7. PMID: 23879202.
      View in: PubMed
    114. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6. PMID: 23795711.
      View in: PubMed
    115. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol. 2013 Jun 15; 190(12):6681-93. PMID: 23686488.
      View in: PubMed
    116. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2013 Jul; 162(1):138-41. PMID: 23590726.
      View in: PubMed
    117. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9. PMID: 23545991.
      View in: PubMed
    118. Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program. 2013; 2013:553-60. PMID: 24319231.
      View in: PubMed
    119. Fowler N, Oki Y. Developing novel strategies to target B-cell malignancies. Am Soc Clin Oncol Educ Book. 2013; 366-72. PMID: 23714549.
      View in: PubMed
    120. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):99-105. PMID: 23276888.
      View in: PubMed
    121. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 01; 31(1):88-94. PMID: 23045577.
      View in: PubMed
    122. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23. PMID: 22677155.
      View in: PubMed
    123. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28; 119(26):6373-8. PMID: 22586182.
      View in: PubMed
    124. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5. PMID: 22015451.
      View in: PubMed
    125. Fowler NH. Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma. P T. 2011 Sep; 36(9):590-8. PMID: 22346327.
      View in: PubMed
    126. Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011 Sep 01; 29(25):3389-95. PMID: 21810687.
      View in: PubMed
    127. Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT detecting thyroid plasmacytoma after the successful treatment of gastric large B-cell lymphoma. Clin Nucl Med. 2011 Apr; 36(4):317-9. PMID: 21368613.
      View in: PubMed
    128. Mazloom A, Rodriguez A, Ha CS, Medeiros LJ, Wogan C, Shihadeh F, Allen P, Fowler N, Dabaja B. Incidence of gastric involvement in patients with nongastrointestinal extranodal marginal zone lymphoma. Cancer. 2011 Jun 01; 117(11):2461-6. PMID: 24048794.
      View in: PubMed
    129. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010 Sep 20; 28(27):4170-6. PMID: 20713859.
      View in: PubMed
    130. Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma. 2010 Jul; 51(7):1217-24. PMID: 20443676.
      View in: PubMed
    131. Goldman L, Ezzat S, Mokhtar N, Abdel-Hamid A, Fowler N, Gouda I, Eissa SA, Abdel-Hamid M, Loffredo CA. Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control. 2009 Aug; 20(6):981-7. PMID: 19263231.
      View in: PubMed
    132. Fowler N, Younes A. There will be blood: targeting tumor vasculature. Blood. 2009 Mar 05; 113(10):2121-2. PMID: 19264922.
      View in: PubMed
    133. Fowler N, Asatiani E, Cheson B. Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma. Leuk Lymphoma. 2008 Jan; 49(1):156-8. PMID: 18203026.
      View in: PubMed
    134. Fowler NO. Recurrent pericarditis. Cardiol Clin. 1990 Nov; 8(4):621-6. PMID: 2249216.
      View in: PubMed
    135. Fowler NO, Harbin AD. Recurrent acute pericarditis: follow-up study of 31 patients. J Am Coll Cardiol. 1986 Feb; 7(2):300-5. PMID: 3944348.
      View in: PubMed
    136. Chou TC, Fowler NO, Gabel M, van der Bel-Kahn J, Feltner EJ. Electrocardiographic and hemodynamic changes in experimental right ventricular infarction. Circulation. 1983 Jun; 67(6):1258-67. PMID: 6851020.
      View in: PubMed
    137. Chou TC, Van der Bel-Kahn J, Allen J, Brockmeier L, Fowler NO. Electrocardiographic diagnosis of right ventricular infarction. Am J Med. 1981 Jun; 70(6):1175-80. PMID: 7234888.
      View in: PubMed
    138. Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol. 1976 Feb; 37(2):223-30. PMID: 2004.
      View in: PubMed
    139. Picardi JL, Kauffman CA, Schwarz J, Holmes JC, Phair JP, Fowler NO. Pericarditis caused by Histoplasma capsulatum. Am J Cardiol. 1976 Jan; 37(1):82-8. PMID: 1244738.
      View in: PubMed
    140. Bloomfield SS, Romhilt DW, Chou TC, Fowler NO. Natural history of cardiac arrhythmias and their prevention with quinidine in patients with acute coronary insufficiency. Circulation. 1973 May; 47(5):967-73. PMID: 4574570.
      View in: PubMed
    141. Romhilt DW, Bloomfield SS, Chou TC, Fowler NO. Unreliability of conventional electrocardiographic monitoring for arrhythmia detection in coronary care units. Am J Cardiol. 1973 Apr; 31(4):457-61. PMID: 4571161.
      View in: PubMed
    142. Fowler NO. "Preinfarctional" angina. A need for an objective definition and for a controlled clinical trial of its management. Circulation. 1971 Nov; 44(5):755-8. PMID: 5115067.
      View in: PubMed
    143. Bloomfield SS, Romhilt DW, Chou TC, Fowler NO. Quinidine for prophylaxis of arrhythmias in acute myocardial infarction. N Engl J Med. 1971 Oct 28; 285(18):979-86. PMID: 4937690.
      View in: PubMed
    144. Kamper D, Chou TC, Fowler NO, Witt RL, Bloomfield S. The reliability of electrocardiographic criteria of chronic obstructive lung disease. Am Heart J. 1970 Oct; 80(4):445-52. PMID: 5471205.
      View in: PubMed
    145. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia.
    146. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology.
    147. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma. The Lancet Oncology. 15:69-77.
    148. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology.
    149. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology.
    150. Non-Hodgkin Lymphomas. 274-295.
    151. Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro-Oncology. 18:575-581.
    152. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthalmic Plastic and Reconstructive Surgery.
    153. The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia. Leukemia and Lymphoma.
    154. Survival outcomes of primary intraocular lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials.
    155. The landscape of new drugs in lymphoma. Nature Reviews Clinical Oncology.
    156. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. British Journal of Haematology.
    157. Idelalisib in the management of lymphoma. Blood. 128:331-336.
    158. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    159. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Annals of Oncology. 27:778-787.
    160. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. Leukemia and Lymphoma. 1-3.
    161. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 101:531-540.
    162. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiation Oncology. 10.
    163. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.
    164. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. 100:e454-e457.
    165. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. British Journal of Haematology.
    166. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 100:e272-e274.
    167. Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. Leukemia and Lymphoma. 1-7.
    168. Synchronous presentation of intra-nodal follicular dendritic cell sarcoma and Castleman disease. American Journal of Hematology.
    169. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leukemia and Lymphoma. 57:34-38.
    170. Chemotherapy-free treatment of follicular lymphoma. ONCOLOGY (United States). 29:769-772.
    171. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology. 27:895-901.
    172. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN). The Lancet Oncology.
    173. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. British Journal of Haematology.
    174. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma. British Journal of Haematology. 175:290-299.
    FOWLER's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description